-
Mashup Score: 0
With the FDA clearance of an investigational new drug application, a phase 1 clinical trial evaluating NST-628 will start in mid-2024.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
With the FDA clearance of an investigational new drug application, a phase 1 clinical trial evaluating NST-628 will start in mid-2024.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
The GI cancer space has “made huge strides” in recent years, which opened more options for patients with a type of esophageal cancer, an expert said.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet
-
Mashup Score: 1FDA Approves Safety Label Changes for Fluorouracil Injection - 6 day(s) ago
The FDA strengthened safety warnings for fluorouracil due to dihydropyrimidine dehydrogenase deficiency that can cause severe adverse effects.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
Siemens Healthineers announced today that the FDA granted clearance for its Ciartic Move mobile C-arm with self-driving capabilities.
Source: www.massdevice.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 0
The FDA has cleared Sequel’s twiist, a novel automated insulin delivery system, expanding patient choice for individuals with type 1 diabetes.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 0Reacting to the FDA Approval of Fluticasone Propionate Nasal Spray, with James Palmer, MD - 10 day(s) ago
James Palmer, MD, provides perspective on the FDA’s decision to approve fluticasone propionate nasal spray for adults with chronic rhinosinusitis without nasal polyps.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 4FDA Warns of T-Cell Malignancy Risk in CAR-T Immunotherapies | ASH Clinical News | American Society of Hematology - 13 day(s) ago
The U.S. Food and Drug Administration (FDA) issued a warning about the risk of T-cell malignancies in patients who have received BCMA- or CD19-directed autologous chimeric antigen receptor (CAR) T-cell immunotherapies. The warning followed the receipt of reports from clinical trials and post-marketing adverse event sources detailing T-cell malignancy occurrences in this patient population. A press release from the FDA noted that the benefits of these therapies still outweigh this risk, but the need for
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1
Matthew J. Frigault, MD, MS, discussed what a community oncologist should know about the ongoing FDA investigation of chimeric antigen receptor T-cell therapies.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
Following changes to the manufacturing process, the phase 1 study of NX-2127 in B-cell malignancies has been cleared to continue by the FDA.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
The #FDA granted clearance to the investigational new drug application for NST-628 for the treatment of patients with advanced solid tumors with genetic alterations in the RAS-MAPK pathway. https://t.co/eEwXYejN63